Goin Kathleen, Chief Operating Officer of Palvella Therapeutics (PVLA), has filed 60 Form 4 transactions, all in that single company. The pattern is one-sided: her total sell value is $6,043,761.64, with zero open-market purchases and zero acquisitions. Every recent trade is either an open-market sale (code S) or an option exercise (code M), and the exercises are small relative to the sales that follow them.
The most recent cluster, dated October 21, 2026, shows three sales worth $76,600.30, $208,148.56, and $252,558.52, paired with two option exercises valued at $19,503.84 and $15,458.10. That same structure repeats on September 16, 2026, with sales of $253,464.58, $150,685.72, and $250,772.62, and on August 19, 2026, with five sales ranging from $15,870.16 to $303,292.20. July 15, 2026 had four sales totaling $642,191.48, and June 17, 2026 had two sales of $2,805.75 and $210,047.25.
In the last six months, Goin has filed 17 sale transactions and no purchases. The option exercises are mechanical events, not discretionary buys, and the sales are the dominant signal. The dollar values are consistent with a COO periodically liquidating vested shares, with the largest single sale at $303,292.20 in August and the smallest at $2,805.75 in June. There is no recent acquisition activity of any kind, and the selling bias is uniform across every filing period in the data.
AI-assisted summary